Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
2-oxopropyl-CoM reductase (carboxylating) (abbreviated 2-KPCC) is a bacterial oxidoreductase enzyme, formally classified under EC 1.8.1.5, that catalyzes the conversion of 2-oxopropyl-coenzyme M (2-oxopropyl-CoM) to acetoacetate, free coenzyme M, and NADPH. It is a member of the NADPH:disulfide oxidoreductase family, which includes glutathione reductase and thioredoxin reductase, but is unique in its ability to mediate both reductive cleavage of a thioether bond and subsequent carboxylation. This enzyme participates in the microbial pathway for catabolism of propylene in species like Xanthobacter autotrophicus, but has no known therapeutic, disease-modifying, or biomarker role in human health or disease. Its structure reveals an FAD-containing, DSOR-family fold with an adapted active site specialized for its unique chemistry[1][2][3][4][8].
Catalyzes reductive cleavage of thioether linkage in 2-oxopropyl-CoM, then carboxylates the cleavage product to yield acetoacetate and free coenzyme M[2][3][8]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 2-oxopropyl-CoM reductase (carboxylating) (2-KPCC).